Overview of Drug Treatment

  • Alan J. Gelenberg

Abstract

As the history of medicine goes, the drug treatment of psychiatric outpatients is a comparatively new topic. Before the modern era of pharmacotherapy blossomed around the midpoint of this century, psychiatrists and other physicians had a few classes of drugs available that could serve mostly as adjuncts to various nonbiological approaches. Sedatives—such as barbiturates, bromides, and chloral hydrate—could assist in promoting sleep and could sometimes produce temporary relief of anxiety; stimulants might prompt a temporary surge in energy and sometimes a boost in spirits; but for the most part, psychiatry could expect little help from the pharmacopoeia.

Keywords

Antipsychotic Drug Panic Disorder Tardive Dyskinesia Biological Therapy Borderline Personality Disorder 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Adler, L., Angrist, B., Pesselow, E., Corwin, J., Maslansky, R., and Rotrosen, J. (1986). A controlled assessment of propranolol in the treatment of neuroleptic-induced akathisia. British Journal of Psychiatry, 148, 701–707.CrossRefGoogle Scholar
  2. Anath, J., and Lin, K-M. (1986). Propranolol in psychiatry: Therapeutic uses and side effects. Neuropsychobiology, 15, 20–27.CrossRefGoogle Scholar
  3. Biederman, J. (1986). Desipramine in attention deficit disorder. Biological Therapies in Psychiatry, 9, 29–32.Google Scholar
  4. Brotman, A. W. (1984). Antidepressants and anticonvulsants: Magic bullets for bulimia? Biological Therapies in Psychiatry, 7, 10–11.Google Scholar
  5. Brotman, A. W. (1985). Antidepressant treatment for cocaine abuse. Biological Therapies in Psychiatry, 8, 8.Google Scholar
  6. Brotman, A. W., Falk, W. E., and Gelenberg, A. J. (1987). Pharmacologic treatment of acute depressive subtypes. In H. Meltzer (Ed.), Psychopharmacology: A generation of progress ( 3rd ed. ). New York: Raven Press.Google Scholar
  7. Dawson, G. W., Jue, S. G., and Brogden, R. N. (1984). Alprazolam: A review of its pharmacodynamic properties and efficacy in the treatment of anxiety and depression. Drugs, 27, 132–147.PubMedCrossRefGoogle Scholar
  8. Donaldson, S. R. (1983). The benzodiazepine hypnotics. Biological Therapies in Psychiatry, 6, 37–40.Google Scholar
  9. Elsasser, G. N., and Anderson, R. K. (1986). Senile dementia: Treatment with vasodilators. Hospital Formulary, 21, 197–203.Google Scholar
  10. Falk, W. E. (1985). Carbamazepine (Tegretol) for manic-depressive illness: An update. Biological Therapies in Psychiatry, 8, 21–24.Google Scholar
  11. Falk, W. E. (1986). Beta blockers for aggression. Biological Therapies in Psychiatry, 9, 41–43.Google Scholar
  12. Falloon, I. R. H., Boyd, J. L., McGill, C. W., Razani, J., Moss, H. B., and Gilderman, A. M. (1982). Family management in the prevention of exacerbations of schizophrenia: A controlled study. New England Journal of Medicine, 306, 1437–1440.PubMedCrossRefGoogle Scholar
  13. Gelenberg, A. J. (1983). Insomnia. In E. L. Bassuk, S. C. Schoonover, and A. J. Gelenberg (Eds.), The practioner’s guide to psychoactive drugs (2nd ed„ pp. 203–220 ). New York: Plenum Medical Book Co.Google Scholar
  14. Gelenberg, A. J. (1984a). The DST in even greater perspective. Massachusetts General Hospital Newsletter, Biological Therapies in Psychiatry, 7, 1.Google Scholar
  15. Gelenberg, A. J. (1984b). Patients with affective illness: Are they more prone to develop TD? Biological Therapies in Psychiatry, 7, 6.Google Scholar
  16. Gelenberg, A. J. (1985). Mood disorders: Preventing recurrences. Biological Therapies in Psychiatry, 8, 5–6.Google Scholar
  17. Gelenberg, A. J. (1986a). Prophylactic and maintenance antiparkinson medication. Biological Therapies in Psychiatry, 9, 33–35.Google Scholar
  18. Gelenberg, A. J. (1986b). Propranolol (Inderal) for schizophrenia: A review and new data. Biological Therapies in Psychiatry, 9, 13–14.Google Scholar
  19. Gelenberg, A. J. (1989). Psychiatric disorders. In D. M. Paige (Ed.), Manual of clinical nutrition ( 2nd ed., pp. 419–428 ). Pleasantville, NJ: Nutrition Publications.Google Scholar
  20. Gelenberg, A. J., Wojcik, J., Falk, W. E., Coggins, C. H., Brotman, A. W., Rosenbaum, J. F., LaBrie, R. A., and Kerman, B. J. (1987). Effects of lithium on the kidney. Acta Psychiatrica Scandinavia, 75, 29–34.CrossRefGoogle Scholar
  21. Gelenberg, A. J., Dorer, D., Wojcik, J., Falk, W. E., Brotman, A. W., and Leahy, L. (1988). Lecithin for tardive dyskinesia. Unpublished manuscript.Google Scholar
  22. Hartmann, E. L. (1986). Effect of L-tryptophan and other amino acids on sleep. Nutrition Reviews, Supplement, 70–73.Google Scholar
  23. Jenike, M. A. (1986). Somatic treatments in obsessive-compulsive disorders. In M. A. Jenike, L. Baer, and W. E. Minichiello (Eds.), Obsessive compulsive disorder: Theory and management. Littleton, MA: PSG.Google Scholar
  24. Kane, J. M. (1983). Low dose medication strategies in the maintenance treatment of schizophrenia. Schizophrenia Bulletin, 9, 528–532.PubMedCrossRefGoogle Scholar
  25. Kane, J. M. ( 1986, March). Outpatient treatment of schizophrenia. Paper read before the symposium Antipsychotic drug therapy: Current Concepts and Future Trends, Key Biscayne, Florida.Google Scholar
  26. Lipinski, J. F., Zubenko, G. S., Cohen, B. M., and Barreira, P. J. (1983). Propranolol in the treatment of neuroleptic-induced akathisia (letter to editor). Lancet, 1, 685–686.CrossRefGoogle Scholar
  27. Manchanda, R., and Hirsch, S. R. (1986). Does propranolol have an antipsychotic effect? A placebo-controlled study in acute schizophrenia. British Journal of Psychiatry, 148, 701–707.PubMedCrossRefGoogle Scholar
  28. McEvoy, J. P. (1986). The neuroleptic threshold as a marker of minimum effective neuroleptic dose. Comprehensive Psychiatry, 27, 327–335.PubMedCrossRefGoogle Scholar
  29. Plenge, P., and Mellerup, E. T. (1986). Lithium and the kidney: Is one daily dose better than two? Comprehensive Psychiatry, 27, 336–342.CrossRefGoogle Scholar
  30. Prien, R. F., and Gelenberg, A. J. (1989). Alternatives to lithium for the preventive maintenance treatment of bipolar disorder. American Journal of Psychiatry, 146, 840–848.PubMedGoogle Scholar
  31. Prien, R. F., Kupfer, D. J., Mansky, P. A., Small, J. G., Tuason, V. B., Voss, C. B., and Johnson, W. E. (1984). Drug therapy in the prevention of recurrence in unipolar and bipolar affective disorders. Archives of General Psychiatry, 41, 1096–1104.PubMedCrossRefGoogle Scholar
  32. Quitkin, F. M. (1985). The importance of dosage in prescribing antidepressants. British Journal of Psychiatry, 147, 593–597.PubMedCrossRefGoogle Scholar
  33. Rickles, K., and Schweizer, E. E. (1986). Benzodiazepines for treatment of panic attacks: A new look. Psychopharmacology Bulletin, 22, 93–99.Google Scholar
  34. Rosenbaum, J. F. (1986, August). Panic disorder. Drug therapy, 113–114.Google Scholar
  35. Schneider-Helmert, D., and Spinweber, C. L. (1986). Evaluation of L-tryptophan for treatment of insomnia: A review. Psychopharmacology, 89, 1–7.PubMedCrossRefGoogle Scholar
  36. Schopf, J. (1983). Withdrawal phenomena after long-term administration of benzodiazepines: A review of recent investigations. Pharmacopsychiatry, 16, 1–8.CrossRefGoogle Scholar
  37. Zubenko, G. S., Cohen, B. M., Lipinski, J. F., and Jonas, J. M. (1985). Use of clonidine in treating neurolepticinduced akathisia. Psychiatry Research, 13, 253–259.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1990

Authors and Affiliations

  • Alan J. Gelenberg
    • 1
  1. 1.Department of PsychiatryUniversity of Arizona College of Medicine, Health Sciences CenterTucsonUSA

Personalised recommendations